Business Wire - October 1, 2004
LabNow's novel sensor technology system offers the potential to analyze blood and other fluid samples extremely rapidly and inexpensively. It will have direct applicability to the healthcare field as a diagnostic tool and potential applications beyond the medical field, including homeland security, environmental testing, and food safety. "The introduction of the CD4Now diagnostic test gives us the opportunity to revolutionize the way that HIV/AIDS is managed worldwide," said Richard Hawkins, the company's president and chief executive officer. "Considering the tens of millions of people who will benefit from this test, the potential impact is huge. We are now in the right position to extend the benefits of this exciting technology."
The patented diagnostic tool will feature an automated reader and assay-specific biochips. The CD4 blood test would utilize a single drop of blood and require less than 10 minutes to generate CD4 cell counts that can be used to determine whether a person needs treatment with anti-HIV medications. The test could be used in physician offices or in rural clinics in developing countries. The new product CD4Now would offer significant advantages over current measurement methods, enabling clinicians to determine rapidly and accurately whether anti-viral therapies are needed for their patients, and whether the medications are leading to health improvements.
The technology was originally conceived and developed in the laboratory of Dr. John McDevitt of the University of Texas, and has been licensed exclusively to LabNow. The technology was adapted for HIV-related Point-of-Care diagnostics through a collaboration between McDevitt, and William Rodriguez, MD, of Massachusetts General Hospital, and Bruce Walker, MD, of Massachusetts General Hospital and Howard Hughes Medical Institute.
"The lab-on-a-chip technology combines human diagnostic principles with new advances in microfabrication techniques, nano-chemistry and microfluidic structures. This unique combination of features allows for the creation of ultra-compact and cost effective medical diagnostic equipment," noted John T. McDevitt, University of Texas at Austin chemistry professor. McDevitt and his co-workers invented the relevant microchip technologies. McDevitt also serves as a scientific advisor to LabNow.
"LabNow is the perfect commercialization partner for this technology," said Neil Iscoe, director of the University's Office of Technology Commercialization. "It has assembled a team that can develop the invention into an internationally distributed product."
John Thornton, general partner with Austin Ventures, added, "LabNow's technology has the potential to provide significant improvements in healthcare to HIV/AIDS patients. By developing a new approach to medical diagnostics, LabNow is successfully using technology to directly improve people's lives while building a strong, sustainable business. We're delighted to be involved with LabNow in launching this technology."
About LabNow (www.LabNow.com)
LabNow has developed the LabNow System to conduct healthcare-related diagnostics at the point-of-care. The company will begin marketing a first-of-its-kind test, CD4Now that will rapidly and accurately assess CD4 counts in HIV/AIDS patients to determine their response to antiretroviral therapies.
About Austin Ventures (www.austinventures.com)
Austin Ventures has been working with talented entrepreneurs to build valuable companies since 1979. With $2.4 billion under management, AV is the most active venture capital firm in Texas, and one of the most established in the nation. With a focus on enterprise software, computer and communications hardware, and business services, Austin Ventures invests at all stages of company development, from $100,000 "planned experiments" to $50+ million investments in management buyouts.
CONTACT: LabNow, Inc., Austin
Stephen Ceresia, 512-329-9998 or 512-423-5148 (cellular)
sceresia@labnow.com
SOURCE: LabNow, Inc.
041001
BW041001
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .